Press Releases
September 1, 2020
SBP Closes $10.5 Million Public Offering of Common Stock and Warrants
August 30, 2020
SBP Announces Pricing of $10.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
August 11, 2020
SBP Provides Business Update and Reports Q2 2020 Financial Results
July 16, 2020
SBP Appoints Jennifer K. Simpson, Ph.D., as President and CEO
- Company founder Michael T. Cullen, M.D. will continue to serve as Executive Chairman
May 13, 2020
SBP Provides Business Update and Reports Q1 2020 Financial Results
April 6, 2020
SBP Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer
March 24, 2020
SBP Provides Business Update and Reports Operating Results for FY2019
- Enrollment completed in fourth cohort of Phase 1a/1b trial of SBP-101 in pancreatic cancer; expansion cohort initiated
- Interim Phase 1 data presented at ASCO GI meeting demonstrated tolerability and tumor response in treatment-naïve patients with metastatic pancreatic cancer
January 28, 2020
SBP Initiates Search for CEO
Company founder Dr. Michael T. Cullen intends to continue to serve as Executive Chairman and will continue to serve as President and CEO until a successor is named
January 24, 2020
SBP Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium
- SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel
- Objective Response Rate (ORR) was 62% by RECIST criteria
- Study expansion in patients with pancreatic cancer planned to begin in Q2
View/download press release »
View/download poster presentation »
Events & Presentations